Zentalis Pharmaceuticals shareholders elect three directors at annual meeting

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company whose stock has declined nearly 49% over the past six months, announced the voting results from its 2025 Annual Meeting of Stockholders held on Tuesday. According to an SEC filing, approximately 80.9% of the company’s outstanding common stock was represented at the meeting, with 58,212,103 shares present online or by proxy. InvestingPro analysis indicates the company maintains a strong liquidity position, with cash reserves exceeding debt obligations.

Shareholders elected three Class II directors to serve until the 2028 Annual Meeting. Scott Myers received the strongest support with 43,014,172 votes in favor, while Karan Takhar and Dr. Luke Walker secured 30,655,734 and 36,599,420 votes respectively.

The meeting also saw the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, with overwhelming support of 58,100,230 votes in favor.

In the third agenda item, shareholders approved the compensation of the company’s named executive officers on an advisory basis, though by a narrower margin. This non-binding proposal received 29,474,720 votes in favor and 17,374,784 votes against.

Based on these results, all proposed items were successfully approved at the meeting, as reported in the company’s 8-K filing with the Securities and Exchange Commission. With the company’s next earnings report scheduled for August 7, 2025, InvestingPro subscribers can access additional insights, including 11 more exclusive ProTips and detailed financial metrics to better understand Zentalis’s market position and growth potential.

In other recent news, Zentalis Pharmaceuticals has been actively advancing its cancer research efforts, as highlighted by its participation in the 2025 American Association for Cancer Research (AACR) Annual Meeting. The company presented significant findings on azenosertib, its investigational WEE1 kinase inhibitor, showcasing its potential in targeting genetic mutations in cancer cells and demonstrating synergistic anti-tumor activity when combined with other agents. In parallel, Zentalis shared updates from the DENALI Phase 2 trial at the 2025 SGO Annual Meeting, where azenosertib achieved an objective response rate of 34.9% among patients with Cyclin E1+ tumors, showing improved outcomes over previous data.

Analysts from H.C. Wainwright and Stifel have maintained their Buy ratings on Zentalis, with price targets of $10.00 and $9.00, respectively. H.C. Wainwright highlighted the drug’s effectiveness as a biomarker-driven therapy for platinum-resistant ovarian cancer, while Stifel noted the company’s plans to initiate a pivotal Phase 2 study and a concurrent randomized confirmatory study. Zentalis is set to commence enrollment for dose confirmation in PROC patients, following a constructive dialogue with the FDA.

The company’s strong cash reserves of $371 million further support its research initiatives and potential market growth. These developments underscore Zentalis Pharmaceuticals’ commitment to advancing cancer treatment and enhancing its pipeline’s clinical outcomes.

Zentalis Pharmaceuticals shareholders elect three directors at annual meeting

Zentalis Pharmaceuticals held its 2025 Annual Meeting of Stockholders, where shareholders elected three Class II directors, ratified Ernst & Young LLP as its independent accounting firm, and approved executive compensation. The company also shared updates on its cancer research, including clinical trial results for azenosertib and analyst ratings. The meeting concluded with all proposed items approved.